TIDMAGL
RNS Number : 7674K
Angle PLC
21 April 2015
For immediate release 21 April 2015
ANGLE plc ("the Company")
OVARIAN CANCER UPDATE
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce that the Medical University of Vienna, one
of its key opinion leaders, has published highly encouraging
results in support of the use of ANGLE's Parsortix system in the
detection of ovarian cancer.
Further to the announcement on 27 January 2015, the Medical
University of Vienna has extended the work undertaken and published
results from its work with the Parsortix system at the American
Association for Cancer Research Annual Meeting 2015 being held in
Philadelphia ("AACR"). AACR is one of the world's largest and most
influential cancer conferences. Following the results announced in
January, the Medical University of Vienna submitted a late-breaking
abstract and we are extremely pleased that this was accepted for
publication as a poster at the conference, which is released today.
Professor Robert Zeillinger and Dr Eva Obermayr are attending the
conference to support the poster.
The poster can be downloaded from the ANGLE website here
http://www.angleplc.com/the-parsortix-system/download-files/. The
poster significantly extends the work announced in January in terms
of the number of patients analysed, the types of cancers considered
and the performance achieved.
The study evaluated a total of 65 patients, comprising 42 cancer
patients and 23 healthy normal volunteers. The cancer patients
consisted of 24 ovarian cancer, 6 cervical cancer, 5 endometrial
cancer and 7 breast cancer cases. The analysis of 7 RNA markers
yielded 100% specificity, which indicates no false positives, a
major problem with existing techniques. The sensitivity of ovarian
cancer was 80% at the point of diagnosis and 78% at relapse, which
compares favourably to the 24.5% sensitivity, which is the best
that has been achieved with other circulating tumour cell ("CTC")
systems.
The important new data shows that a sensitivity of 71% was
achieved with the metastatic breast cancer patients, which is more
than twice as high as achieved in studies using other CTC
systems.
To improve the sensitivity further, the Medical University of
Vienna reanalysed the RNA information using 30 RNA markers with the
thresholds set for 100% specificity. So far this work has been
completed for 13 of the cancer patients. The addition of 23 further
RNA markers yielded an increased sensitivity level averaging 92%
across all the cancer types. Notably the sensitivity and
specificity for the 7 ovarian cancer patients that were re-analysed
were both 100% at diagnosis and at relapse. This meant that all the
ovarian cancer patients were correctly identified using the
Parsortix blood test and there were no false positives or false
negatives. Larger sample sizes will be needed to complete
optimisation and confirm these improved results.
With this new highly sensitive approach, the Medical University
of Vienna undertook analysis of a woman at high risk of developing
ovarian and breast cancer as a result of BRCA1/2 mutation. The
woman appeared healthy, had no symptoms and conventional diagnosis
including ultrasound and the CA-125 serum tumour marker indicated
that she was disease-free. However, like Angelina Jolie, the woman
elected to undergo risk-reducing surgery to remove her ovaries. The
Parsortix blood sample taken prior to surgery indicated that the
woman was positive for ovarian cancer. This was initially thought
to be a false positive. However, contrary to all the medical
expectations and results from conventional diagnosis, when the
surgery was undertaken the woman was in fact found to have ovarian
cancer.
This is only one case but it demonstrates the exceptional
sensitivity of the Parsortix system and may provide a monitoring
option for the approximately 1 in 380 women worldwide who are
BRCA1/2 positive and at high risk of developing cancer.
The Medical University of Vienna is now progressing a
multi-centre prospective clinical study in ovarian cancer, which is
expected to take around 18 months to complete. ANGLE is supporting
this effort as a top priority.
ANGLE's Parsortix system together with the RNA marker panel has
the potential to help inform clinical decision-making for ovarian
cancer patients in:
-- Detection of cancer in high risk or genetically pre-disposed patients (detection)
-- Monitoring therapy and selection of therapies in treatment of
ovarian cancer patients (therapy monitoring)
-- Monitoring of ovarian cancer patients in remission for early
detection of relapse (remission monitoring)
ANGLE estimates that the ovarian cancer sales potential for the
Parsortix system in Europe and the United States would be in excess
of GBP300 million per annum.
Dr Eva Obermayr, Principal Investigator at the Medical
University of Vienna, commented:
"The Parsortix technology contributes to the unprecedented
specificity and sensitivity of the overall approach, by providing a
high purity CTC sample. Parsortix is a label-free technology, and
as such may become the gold standard for ovarian cancer diagnosis.
By combining the Parsortix technology with qPCR analysis, we
achieved an unprecedented high detection rate of cancer, even in
early stage patients, where conventional diagnostic methods
failed."
Professor Robert Zeillinger, Head of the Molecular Oncology
Group at the Medical University of Vienna, commented:
"It is now evident that the Parsortix system has wide
application not just in ovarian cancer but in breast cancer and
other gynaecological cancers as well. We are delighted to be
working with ANGLE to bring this new capability to our patients as
soon as possible."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The prospect of a simple blood test for cancer detection with
such high sensitivity and specificity is extremely exciting. The
results published today by Medical University of Vienna
substantiate the early findings in ovarian cancer and extend the
opportunity into breast cancer and other gynaecological
cancers."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles,
Jane Glover 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
two granted US patents and three extensive families of patents
being progressed worldwide. The system is based on a microfluidic
device that captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The increase in cancer to a 1 in 3 lifetime incidence is set to
drive a multi $billion clinical market. The Parsortix system is
designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCIMMFTMBJTBTA
Angle (LSE:AGL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Angle (LSE:AGL)
Historical Stock Chart
From Nov 2023 to Nov 2024
